Abstract

    Open Access Review Article Article ID: AGGR-5-120

    Development of a new drug for progeria syndrome; Past, Present and Future

    So-mi Kang, Minju Kim and Bum-Joon Park*

    Hutchinson-Gilford progeria syndrome (HGPS) is the best characterized genetic disorder with premature aging features. Classic HGPS is very rare, sporadic orphan disease, inherited in an autosomal dominant manner without gender or ethnic differences. Children with HGPS appear normal at birth, but begin to develop segmental progeroid symptoms within the first years of life. Patients suffer from sarcopenia, lipodystrophy, diabetes, cataracts, atherosclerosis but not cancer and neurodegenerative diseases. Genetic factors that are associated with this syndrome have been identified, mouse models of disease have been developed, and clinical studies have been conducted for many years. Although many medical and treatment approaches were implemented and showed some efficacy, these therapies could not be considered as a complete cure, and more effective therapeutic approaches were needed for HGPS patients. This report introduces a novel drug called progerinin, which is a binding inhibitor of lamin A and progerin, for patients affected with HGPS.

    Keywords:

    Published on: Jun 8, 2020 Pages: 22-25

    Full Text PDF Full Text HTML DOI: 10.17352/aggr.000020
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on AGGR

    Google Reviews 11